Menu Search
Equities

Crossject SA

74C:DEU

Crossject SA

Actions
  • Price (EUR)2.09
  • Today's Change-0.04 / -1.88%
  • Shares traded0.00
  • 1 Year change-39.42%
  • Beta--
Data delayed at least 15 minutes, as of May 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Crossject SA is a France-based company that designs and develops medical injection systems. The Company specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous, and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The Company's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance, and comfort. The Company has industrial partnerships with Hirtenberger and Recipharm. It provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.

  • Revenue in EUR (TTM)500.00k
  • Net income in EUR-9.84m
  • Incorporated2001
  • Employees110.00
  • Location
    Crossject SAParc Mazen-Sully6 Rue Pauline KergomardDIJON 21000FranceFRA
  • Phone+33 380549850
  • Fax+33 148046723
  • Websitehttps://www.crossject.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.